Boston Scientific Corporation (BSX) saw a flurry of investment activity recently. Large investment firms such as
Great Lakes Advisors,
Voleon Capital Management, and
Strs Ohio have dynamically adjusted their positions, with some investing significantly in the company, while others reducing their holdings. Meanwhile,
Integrity Alliance LLC and
Axiom Investors LLC DE newly acquired large stakes.
Acadian Asset Management LLC maintains a substantial $61.14 million position. The bio-tech's buy rating by
Needham & Company LLC was reaffirmed, indicating continued confidence. As a notable deal, Boston Scientific has purchased the
BioEnvelope business from Elutia for $88 million, which could provide lucrative development opportunities. Following leadership changes and the rollout of a notable FDA approved device
FARAPULSE, the company's valuation is under scrutiny, despite the company reaching a new 12-month high post analyst upgrade.
RBC and
Oppenheimer are taking bullish stances, raising their price targets to $125 and $118, respectively, following strong Q2 results. Additionally, Boston Scientific has completed a
€1.5 billion offering of senior notes, fortifying its financial position.
Boston Scientific Corp BSX News Analytics from Wed, 26 Feb 2025 08:00:00 GMT to Sat, 13 Sep 2025 22:16:51 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
